Efficacy of Voriconazole, Isavuconazole, Fluconazole, and Anidulafungin in the treatment of emerging Candida auris using an immunocompromised murine model of disseminated candidiasis

Antimicrob Agents Chemother. 2021 Jul 6:AAC0054921. doi: 10.1128/AAC.00549-21. Online ahead of print.


Antifungal activity of anidulafungin, voriconazole, isavuconazole, and fluconazole in the treatment of Candida auris was determined in vitro and in vivo. Minimum inhibitory concentrations (MICs) for Anidulafungin, voriconazole, isavuconazole, fluconazole, and amphotericin B were 0.5, 1, >64, 0.25, and 4 μg/mL, respectively. Significant in vivo efficacy was observed in anidulafungin- and voriconazole-treated groups in survival and reduction in kidney tissue fungal burden compared to the untreated group (P-value of < 0.001 and 0.044, respectively). Our data showed that anidulafungin and voriconazole had comparable efficacy against C. auris, whereas isavuconazole did not show significant in vivo activity.

PMID:34228541 | DOI:10.1128/AAC.00549-21